Company intelligence / Profile preview

Trinitas Global

Ownership: Private
Development stage: Other

Overview

Trinitas Global is a research and data science company specializing in predictive biomarker analysis. Its main offering is the Trinitas Risk Assessment platform, which uses existing biomarker data and custom diagnostic panels to assess population-level risks for adverse immune responses. The company integrates this platform into clinical workflows to optimize treatment pathways and improve patient outcomes. It also collaborates with institutional research organizations on therapeutic response programs and novel treatments.

Therapeutic areas: ImmunologyOther
Modalities: Diagnostic panelPredictive biomarker analysis
Industry: Digital Health Medical Devices

Partnerships

Institutional research organizations

Beyond the preview

Go deeper on Trinitas Global.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Trinitas Global.

Explore the full profile